EyePoint Pharmaceuticals Reports Data From Ongoing P-II (VERONA) Study of Duravyu in Diabetic Macular Edema (DME)
Shots:
- EyePoint reported interim 16-week data from a P-II (VERONA) study investigating Duravyu (2.7mg) using sustained-release Durasert E technology to treat DME
- The P-II (VERONA) study (n=27) at 16wks. showed early and sustained improvement in both BCVA and CST measured through OCT. BCVA and CST improved by +8.9 letters & 68.1 microns vs +3.2 letters & 30.5 microns for aflibercept from the baseline and 82% of eyes receiving Duravyu were supplement-free vs 50% in the aflibercept; visual and anatomical gains were observed at 4Wks. indicating Duravyu's immediate bioavailability
- Individuals that continued till 24weeks. showed a positive trend in BCVA and anatomy with continued positive safety and tolerability profile
Ref: EyePoint Pharmaceuticals | Image: EyePoint Pharmaceuticals
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
